Gain Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited. Gain Therapeutics is a pre-revenue biotechnology company developing small-molecule therapeutics using its Magellan platform. Its lead clinical-stage candidate, GT-02287, is being developed for GBA1 Parkinson’s disease.
Financial highlights
| Metric | Q1 2024 | Q1 2023 or prior period |
|---|---|---|
| Revenue | $0 | $55,180 |
| Research and development expense | $2.51 million | $2.79 million |
| General and administrative expense | $1.87 million | $2.49 million |
| Total operating expenses | $4.38 million | $5.28 million |
| Net loss | $4.01 million | $5.14 million |
| Basic and diluted loss per share | $0.22 | $0.43 |
| Cash used in operating activities | $3.59 million | $4.22 million |
- At March 31, cash and cash equivalents were $10.64 million and current marketable securities were $2.02 million, or $12.66 million combined, versus $16.79 million at December 31, 2023.
- Current assets were $13.86 million and current liabilities were $5.00 million. Total liabilities were $5.94 million; reported loans were approximately $0.51 million, alongside operating lease liabilities. Stockholders’ equity was $8.64 million.
- Cash, cash equivalents and restricted cash declined $1.16 million during the quarter. Investing cash inflow of $3.02 million mainly reflected maturities of marketable securities; financing cash outflow was $0.15 million, including $0.28 million of offering costs.
- No operating margin is presented; the company had no revenue in Q1 2024. Interest income was $115,000 and foreign-exchange gain was $268,000.
Changes versus the prior comparable quarter
- Net loss narrowed by $1.12 million, while operating expenses fell by $0.91 million. R&D expense decreased by $284,000, including $204,000 of research-grant funding recorded as a reduction of expense. G&A expense decreased by $623,000, primarily due to lower legal and professional fees and stock-based compensation.
- Revenue declined by $55,180 because there was no collaboration revenue in Q1 2024; the Zentalis collaboration had concluded in 2023.
- Foreign exchange moved from a $43,000 loss in Q1 2023 to a $268,000 gain in Q1 2024, mainly reflecting Swiss franc/U.S. dollar movements.
- Common shares outstanding rose from 16.21 million at December 31 to 18.04 million at March 31, mainly reflecting exercise of pre-funded and public warrants. The company also reported 4.52 million warrants outstanding at quarter-end.
Outlook, risks and notable developments
- Going concern: Management reported substantial doubt about the company’s ability to continue as a going concern. It expects existing resources to fund operations into the first quarter of 2025, but not for at least 12 months from issuance of the financial statements. Additional capital or other funding is needed to continue beyond Q1 2025; no committed external funding or credit line was reported.
- Management is considering public or private equity, convertible debt, collaborations, licensing, grants and cost reductions. Financing may be unavailable or dilutive, and failure to raise funds could require delays or reductions to development, other operational changes, or cessation of operations.
- In February 2024, the company began the multiple ascending dose (MAD) portion of the Phase 1 GT-02287 trial after completing the single ascending dose (SAD) portion. It expected to complete MAD in Q2 2024. After quarter-end, on April 24, it announced that SAD results showed the candidate was generally well tolerated through the highest planned dose, with no serious adverse events. These are early clinical findings and do not establish efficacy.
- Management expects R&D expenses to increase as development advances. Research commitments were $3.4 million for activities expected within one year. The company is also pursuing partnering opportunities and reviewing costs to improve cash efficiency.
- Key risks include clinical and regulatory uncertainty, difficulty enrolling patients in rare-disease trials, reliance on third-party research and manufacturing providers, the need to protect licensed intellectual property, and exposure to foreign exchange and capital-market conditions. Management said disclosure controls were effective as of March 31, 2024; no material legal proceedings were reported.
Important facts for investors to verify
- Updated cash runway, quarterly cash burn and funding plans, including whether financing or partnering transactions are completed on acceptable terms.
- Subsequent progress and complete safety, exposure and other available results from the GT-02287 MAD and Phase 1 program; distinguish safety findings from evidence of efficacy.
- Actual timing and use of the $3.4 million research commitments, grant reimbursements and planned cost reductions.
- Potential dilution from outstanding warrants, options and equity awards, as well as the terms of any future financing.
- Whether clinical, regulatory, manufacturing, enrollment, foreign-exchange or intellectual-property developments alter the company’s operating plan or stated cash runway.